Sage touts first win in $3B Biogen pact, but safety profile, doubts over data cloud road ahead
The big test is still weeks or months away, but Sage and Biogen have scored their first, albeit narrow, win since signing their $3.1 billion deal last year.
The biotechs announced Monday that SAGE-324, the second major molecule in the pact, had cleared a Phase II trial for essential tremor, a progressive disorder that causes involuntary muscle movement in about 6.4 million Americans. Patients in the 67-person study who received the drug had a 36% reduction of upper limb tremor on a standard medical scale, compared to a 21% reduction for patients on placebo.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.